Abstract: In most human cancers, a large number of proteins with driver mutations are involved in tumor development, implying that multiple fine tuners are involved in cancer formation and/or maintenance. A useful strategy for cancer therapy may therefore be to target multiple cancer type-specific fine tuners. Furthermore, genome-wide association studies of tumor samples have identified a large number of long noncoding (lnc)RNA associated with various types of tumor. In this context we have previously found that C20orf204 (a splice variant of Linc00176) RNA contains a 189 amino acid (AA) long open reading frame (C20orf204-189AA) that is expressed predominantly in hepatocellular carcinoma (HCC). We report here that a protein, C20orf204-189AA, was detected in the nucleus of 14 out of 20 primary HCC, but not in control livers. Strikingly, overexpression of C20orf204-189AA enhanced cell proliferation and ribosomal RNA transcription. C20orf204-189AA is co-localized, and interacted with nucleolin via the C-terminal and with ribosomal RNA via the N-terminal domain. Furthermore, the expression of C20orf204-189AA upregulates the protein level of nucleolin. Nucleolin and C20orf204 mRNA levels in HCC are correlated with tumor differentiation grade and patient survival, suggesting that C20orf204-189AA is a cancer type-specific fine tuner in some HCC that presents itself for potential targeting therapy and cancer biomarker. Thus, cancer cells exhibit remarkable transcriptome alterations partly by adopting cancer-specific splicing isoforms of noncoding RNAs and may participate in tumor development.
|056-70||C20orf204 (118-144) (Human)||100 µg||$250|
|056-72||C20orf204 (146-189) Amide (Human)||100 µg||$305|
|056-83||C20orf204 (24-79) Amide & (118-144) (Human)||100 µg||$495|
|056-66||C20orf204 (24-79) Amide (Human)||100 µg||$350|
|056-85||C20orf204 (83-114) Amide & (146-189) Amide (Human)||100 µg||$460|
|056-68||C20orf204 (83-114) Amide (Human)||100 µg||$255|
|056-74||C20orf204 (87-144) (Human)||100 µg||$315|